Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib
Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib / Guglielmelli, Paola; Mazzoni, Alessio; Maggi, Laura; Kiros, Seble Tekle; Zammarchi, Lorenzo; Pilerci, Sofia; Rocca, Arianna; Spinicci, Michele; Borella, Miriam; Bartoloni, Alessandro; Rossolini, Gian Maria; Annunziato, Francesco; Vannucchi, Alessandro M. - In: AMERICAN JOURNAL OF HEMATOLOGY. - ISSN 0361-8609. - ELETTRONICO. - (2021), pp. 1-1. [10.1002/ajh.26305]
Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib
Guglielmelli, Paola;Mazzoni, Alessio;Maggi, Laura;Kiros, Seble Tekle;Zammarchi, Lorenzo;Pilerci, Sofia;Rocca, Arianna;Spinicci, Michele;Borella, Miriam;Bartoloni, Alessandro;Rossolini, Gian Maria;Annunziato, Francesco;Vannucchi, Alessandro M
2021
Abstract
Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
American J Hematol - 2021 - Guglielmelli - Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
587.56 kB
Formato
Adobe PDF
|
587.56 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
